ID: ALA359756

Max Phase: Preclinical

Molecular Formula: C32H38N2O6S

Molecular Weight: 578.73

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(S(=O)(=O)N(CC(C)C)[C@@H](CCCCNC(=O)OCC2c3ccccc3-c3ccccc32)C(=O)O)cc1

Standard InChI:  InChI=1S/C32H38N2O6S/c1-22(2)20-34(41(38,39)24-17-15-23(3)16-18-24)30(31(35)36)14-8-9-19-33-32(37)40-21-29-27-12-6-4-10-25(27)26-11-5-7-13-28(26)29/h4-7,10-13,15-18,22,29-30H,8-9,14,19-21H2,1-3H3,(H,33,37)(H,35,36)/t30-/m0/s1

Standard InChI Key:  UXBUYQULNOSYKV-PMERELPUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 578.73

Molecular Weight (Monoisotopic): 578.2451

AlogP: 5.80

#Rotatable Bonds: 13

Polar Surface Area: 113.01

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.48

CX Basic pKa:

CX LogP: 6.32

CX LogD: 2.94

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.25

Np Likeness Score: -0.69

References

1. Bouzide A, Sauvé G, Yelle J..  (2005)  Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.,  15  (5): [PMID:15713418] [10.1016/j.bmcl.2004.12.068]

Source

Source(1):

• Scientific Literature